(Press-News.org) Key Takeaways
Immune thrombotic thrombocytopenic purpura, a rare blood clotting disorder, results from an autoimmune attack against an enzyme called ADAMTS13
A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura
Results from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial
A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting throughout the small blood vessels. The group describes the first clinical use of the drug for iTTP in the New England Journal of Medicine.
“The drug is a genetically engineered version of the missing enzyme in iTTP, and we showed that it was able to reverse the disease process in a patient with an extremely severe form of this condition,” said lead author Pavan K. Bendapudi, MD, an investigator in the Division of Hematology and Blood Transfusion Service at Massachusetts General Hospital and an assistant professor of Medicine at Harvard Medical School.
iTTP results from an autoimmune attack against an enzyme called ADAMTS13 that is responsible for cleaving a large protein involved in blood clotting. The current mainstay of therapy for this life-threatening blood disorder is plasma exchange, which removes the harmful autoantibodies and provides extra ADAMTS13. Plasma exchange induces a clinical response in most patients but can restore at best only about half of normal ADAMTS13 activity. By contrast, a recombinant form of human ADAMTS13 (rADAMTS13) offers the possibility of greatly increased ADAMTS13 delivery.
rADAMTS13 was recently approved for patients with congenital thrombotic thrombocytopenic purpura, which occurs in patients born with complete loss of the ADAMTS13 gene. It's questionable whether rADAMTS13 could be effective in iTTP given the presence of inhibitory anti-ADAMTS13 autoantibodies, but Bendapudi and his colleagues received permission from the US Food and Drug Administration to utilize rADAMTS13 donated from the manufacturer under a compassionate use protocol in a dying patient with treatment-resistant iTTP.
“We found that rADAMTS13 rapidly reversed this patient’s disease process despite the current dogma that inhibitory autoantibodies against ADAMTS13 would render the drug useless in this condition,” said Bendapudi. “We were the first physicians to use rADAMTS13 to treat iTTP in the United States, and in this case it helped to save the life of a young mother.”
Bendapudi noted that the infused rADAMTS13 overwhelmed the inhibitory autoantibodies in the patient and reversed the thrombotic effects of iTTP. This impact was observed almost immediately upon administration of rADAMTS13, after daily plasma exchange had failed to induce remission.
“I think rADAMTS13 has the potential to replace the current standard of care in acute iTTP. We will need larger, well-designed trials to evaluate this possibility,” said Bendapudi.
A phase 2b randomized clinical trial of rADAMTS13 in iTTP was recently initiated.
Authorship:
Pavan K. Bendapudi, Brody H. Foy, Sarah B. Mueller, Jun Liu, Louis M. Feingold, Kristen E. Burke, Wendy Cruz, Maria Y. Chen, Emily S. Lau, Rachel L. Goldberg, Ishan Tatake, Shelby C. Wilkinson, Brian J. Carney, James R. Stone, Doyun Park, Alzira Rocheteau Monteiro Avelino, Sajjad Hassan, Chester Andrzejewski, Kristen N. Ruby, Kenneth D. Friedman, Patricia A.R. Brunker, Rebecca K. Leaf, John Higgins, Walter H. Dzik, Jonathan A. Stefely, and Robert S. Makar.
Funding:
Research support was provided by the National Institutes of Health and the Luick Family Fund of the Department of Pathology at Massachusetts General Hospital.
Paper cited:
Bendapudi, P. K., Foy, B. H., Mueller, S. B., Liu, J., Feingold, L. M., Burke, K. E., Cruz, W., Chen, M. Y., Lau, E. S., Goldberg, R. L., Tatake, I., Wilkinson, S. C., Carney, B. J., Stone, J. R., Park, D., Avelino, A. R., Hassan, S., Andrzejewski, C., Ruby, K. N., Friedman, K. D., … Makar, R. S. (2024). Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. The New England journal of medicine, 390(18), 1690–1698. https://doi.org/10.1056/NEJMoa2402567
END
Clinicians report success with first test of drug in a patient with life-threatening blood clotting disorder
Results from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial
2024-05-17
ELSE PRESS RELEASES FROM THIS DATE:
NIH study shows chronic wasting disease unlikely to move from animals to people
2024-05-17
WHAT:
A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people. The findings, from National Institutes of Health scientists and published in Emerging Infectious Diseases, are consistent with decades of similar research in animal models at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Prion diseases are degenerative diseases found in some mammals. These diseases primarily involve deterioration of the brain but also can affect the eyes and other organs. ...
Scientists discover mechanism of sugar signaling in plants
2024-05-17
UPTON, N.Y. — Proteins are molecular machines, with flexible pieces and moving parts. Understanding how these parts move helps scientists unravel the function a protein plays in living things — and potentially how to change its effects. Biochemists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and colleagues at DOE’s Pacific Northwest National Laboratory (PNNL) have just published a new example of how one such molecular machine works.
Their paper in the journal Science Advances describes how the moving parts of ...
Cleveland Clinic research finds VISTA directly blocks T-cells from functioning in immunotherapy
2024-05-17
A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
The study, published in Science Immunology, explains that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote bone and fat development. When VISTA binds to LRIG1, the researchers found, LRIG1 sends signals that suppress T cell replication, survival ...
Pagan-Christian trade networks supplied horses from overseas for the last horse sacrifices in Europe
2024-05-17
Horses crossed the Baltic Sea in ships during the Late Viking Age and were sacrificed for funeral rituals, according to research from Cardiff University.
Published in the journal Science Advances, studies on the remains of horses found at ancient burial sites in Russia and Lithuania show that they were brought overseas from Scandinavia utilising expansive trade networks connecting the Viking world with the Byzantine and Arab Empires.
Up to now, researchers had believed sacrificial horses were always locally-sourced stallions. ...
University of Bristol researchers develop world’s smallest quantum light detector on a silicon chip
2024-05-17
Researchers at the University of Bristol have made an important breakthrough in scaling quantum technology by integrating the world’s tiniest quantum light detector onto a silicon chip.
A critical moment in unlocking the information age was when scientists and engineers were first able to miniaturise transistors onto cheap micro-chips in the 1960s.
Now, for the first time, University of Bristol academics have demonstrated the integration of a quantum light detector – smaller than a human hair – onto a silicon chip, moving us one step closer to the age of quantum technologies using light.
Making high performance electronics ...
Gut bacteria boost immune response to fight tumors
2024-05-17
Roughly one in five cancer patients benefits from immunotherapy – a treatment that harnesses the immune system to fight cancer. Such an approach to beating cancer has seen significant success in lung cancer and melanoma, among others. Optimistic about its potential, researchers are exploring strategies to improve immunotherapy for cancers that don’t respond well to the treatment, with the hope of benefiting more patients.
Now, researchers at Washington University School of Medicine in St. Louis have found, in ...
How heatwaves are affecting Arctic phytoplankton
2024-05-17
The basis of the marine food web in the Arctic, the phytoplankton, responds to heatwaves much differently than to constantly elevated temperatures. This has been found by the first targeted experiments on the topic, which were recently conducted at the Alfred Wegener Institute’s AWIPEV Station. The phytoplankton’s behaviour primarily depends on the cooling phases after or between heatwaves, as shown in a study just released in the journal Science Advances.
Heatwaves, which we’ve increasingly seen around the globe in recent years, are also becoming more and ...
NUS scientist Professor Lim Chwee Teck elected Fellow of the Royal Society
2024-05-17
Professor LIM Chwee Teck, Director of the Institute for Health Innovation & Technology at the National University of Singapore (NUS iHealthtech) and NUSS Professor, has been elected to the prestigious Fellowship of the Royal Society, in recognition of his invaluable contributions to science.
The Royal Society is the world's oldest and most esteemed scientific academy in continuous existence, as well as the United Kingdom’s national academy of sciences. Fellows are elected annually, and candidates are evaluated based on their exceptional achievements in science. This ...
Modern plant enzyme partners with surprisingly ancient protein
2024-05-17
UPTON, N.Y. — Scientists from the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have discovered that a protein responsible for the synthesis of a key plant material evolved much earlier than suspected. This new research explored the origin and evolution of the biochemical machinery that builds lignin, a structural component of plant cell walls with significant impacts on the clean energy industry.
When the first land plants emerged from aquatic environments, they needed to adapt in order to survive.
Chang-Jun Liu, a senior scientist in Brookhaven’s Biology ...
Ion irradiation offers promise for 2D material probing
2024-05-17
Two-dimensional materials such as graphene promise to form the basis of incredibly small and fast technologies, but this requires a detailed understanding of their electronic properties. New research demonstrates that fast electronic processes can be probed by irradiating the materials with ions first.
A collaboration involving researchers at the University of Illinois Urbana-Champaign and the University of Duisburg-Essen has shown that when graphene is irradiated with ions, or electrically charged atoms, the electrons that are ejected ...
LAST 30 PRESS RELEASES:
Milky Way-like galaxy M83 consumes high-speed clouds
Study: What we learned from record-breaking 2021 heat wave and what we can expect in the future
Transforming treatment outcomes for people with OCD
Damage from smoke and respiratory viruses mitigated in mice via a common signaling pathway
New software tool could help better understand childhood cancer
Healthy lifestyle linked to lower diverticulitis risk, irrespective of genetic susceptibility
Women 65+ still at heightened risk of cervical cancer caused by HPV
‘Inflammatory’ diet during pregnancy may raise child’s diabetes type 1 risk
Effective therapies needed to halt rise in eco-anxiety, says psychology professor
Nature-friendly farming boosts biodiversity and yields but may require new subsidies
Against the odds: Endometriosis linked to four times higher pregnancy rates than other causes of infertility, new study reveals
Microplastics discovered in human reproductive fluids, new study reveals
Family ties and firm performance: How cousin marriage traditions shape informal businesses in Africa
Novel flu vaccine adjuvant improves protection against influenza viruses, study finds
Manipulation of light at the nanoscale helps advance biosensing
New mechanism discovered in ovarian cancer peritoneal metastasis: YWHAB restriction drives stemness and chemoresistance
New study links blood metabolites and immune cells to increased risk of urolithiasis
Pyruvate identified as a promising therapeutic agent for ulcerative colitis by targeting cytosolic phospholipase A2
New insights into the clinical impact of IKBKG mutations: Understanding the mechanisms behind rare immunodeficiency syndromes
Displays, imaging and sensing: New blue fluorophore breaks efficiency records in both solids and solutions
Sugar, the hidden thermostat in plants
Personality can explain why some CEOs earn higher salaries
This puzzle game shows kids how they’re smarter than AI
Study suggests remembrances of dead played role in rise of architecture in Andean region
Brain stimulation can boost math learning in people with weaker neural connections
Inhibiting enzyme could halt cell death in Parkinson’s disease, study finds
Neurotechnology reverses biological disadvantage in maths learning
UNDER EMBARGO: Neurotechnology reverses biological disadvantage in maths learning
Scientists target ‘molecular machine’ in the war against antimicrobial resistance
Extending classical CNOP method for deep-learning atmospheric and oceanic forecasting
[Press-News.org] Clinicians report success with first test of drug in a patient with life-threatening blood clotting disorderResults from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial